Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALVOEYE: AVT06 vs EU-Eylea in Neovascular (Wet) Age-related Macular Degeneration
2021-003651-42Phase 3Completed
- Sponsor
- Alvotech
- Start
- Feb 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of AVT06 in exudative macular degeneration (2 arms), sponsored by Alvotech. Primary endpoint: Change in BCVA at Week 8. Started Feb 2022; status: completed.
02
Drugs
AVT06
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2021-003651-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003651-42.